Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities

Inclusion Criteria: An individual will be enrolled in this study if the patient: * Meets the case definition for a probable or a suspected case of CCHF or LF (see below). * Has read and signed the Informed Consent. * Is at least 18 years of age (17, if active military) and not greater than 65 years of age. * Has a blood sample drawn and a type and cross-match ordered for transfusion. * Agrees to collection of required specimens. * Agrees to report any Adverse Events, Serious and Unexpected Adverse Events for the duration of the study. * Agrees to a follow-up visit and to donate blood and urine specimens at day 14 (±2 days) and once between days 28 and 60 after the first dose of IV Ribavirin and to all follow-up visits for anemia or other medical conditions as required by the attending physician. * Woman of childbearing age must have a pregnancy test performed. If negative, she must agree not to become pregnant during treatment and for 7 months after receiving Ribavirin. She also must agree to not breast feed during treatment and for 7 months after receiving Ribavirin. Two reliable forms of effective contraception must be used including one barrier method during treatment and during the 7 month post-treatment period. She will be counseled concerning the risks of IV Ribavirin versus no treatment if the pregnancy test is positive. * Man agrees not to have intercourse with pregnant woman during treatment and for 7 months after receiving Ribavirin, and take precautions to avoid …